A Widely Used Drug Shows a New Potential Effect
Semaglutide, the active ingredient in Ozempic and Wegovy, appears to slow the accumulation of DNA markers linked to biological aging in adults with HIV, according to the first randomized, placebo-controlled human clinical trial to examine this question. The study, led by researchers at the University of California San Diego and published in Nature Communications, provides the earliest human clinical evidence that GLP-1 receptor agonist medications may influence aging processes beyond their established effects on weight, blood sugar, and cardiovascular risk.
